We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Co-Diagnostics, Inc.

Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-a... read more Featured Products: More products

Download Mobile App





Co-Diagnostics Introduces its CoPrimer Technology and Applications at MEDICA 2022

By LabMedica International staff writers
Posted on 15 Nov 2022
Print article
Image: The CoPrimer binding process - No primer dimers, no optimization, real multiplexing (Photo courtesy of Co-Diagnostics)
Image: The CoPrimer binding process - No primer dimers, no optimization, real multiplexing (Photo courtesy of Co-Diagnostics)

Co-Diagnostics, Inc. (Salt Lake City, UT, USA), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, is hosting a booth at the MEDICA 2022 trade fair in Düsseldorf, Germany from 14-17 November. After more than 40 years, MEDICA has become the largest medical trade fair in the world, attracting thousands of exhibitors from more than 50 countries. The company is using the opportunity to generate increased interest in its suite of in vitro diagnostic and research products for COVID-19 and other infectious diseases, and to introduce and promote its CoPrimer technology and applications to a wide audience of international attendees.

Co-Diagnostics’ revolutionary CoPrimer PCR technology is available around the world at cost-efficient pricing. The unique, proprietary structure of CoPrimers molecules creates reactions that are far more specific than competing PCR technologies, to better identify the presence of and distinguish between viruses, pathogens, cancer, or other attributes in agricultural or industrial applications. One of the most important attributes of Co-Diagnostics’ CoPrimer technology is the virtual elimination of “primer-dimers,” the principal source of false positives in diagnostic testing. Primer-dimers are essentially the amplification of errors that can take place during the course of a molecular diagnostic test. These errors dramatically minimize the accuracy of the test and lead to false results and/or inaccurate diagnoses. By virtually eliminating “primer-dimers” from molecular diagnostic testing, CoPrimers assure unparalleled performance of real-time PCR molecular tests.

CoPrimers’ specificity also enables the identification of a broad spectrum of conditions in a single molecular diagnostic test procedure – known as multiplexing – as opposed to conducting discrete individual procedures. Multiplexing enables a single test to identify numerous conditions, attributes, or genetic sequences simultaneously. Multiplexing has enormous implications on cost-efficiencies and time savings in molecular testing, which could prove substantial in a medical situation.

At MEDICA 2022, Co-Diagnostics is also introducing its upcoming Co-Dx PCR Home platform that is powered by the cloud, which is intended to allow for the results to even be transmitted to different destinations as needed. The platform is being designed with the capability to test for a wide variety of diseases and is in line with the company’s aim to disrupt the molecular diagnostics status quo by bringing revolutionary lab-grade PCR testing capabilities - the gold standard in infectious disease testing - into homes and businesses.

Related Links:
Co-Diagnostics, Inc.

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
New
Basophil Activation Test
Flow CAST Kit
New
Automated Biochemistry Analyzer
AutoChem B861

Print article

Channels

Molecular Diagnostics

view channel
Image: A coronal MRI section shows a high-intensity focused ultrasound lesion in the left thalamus of the brain (Photo courtesy of UT Southwestern Medical Center)

Newly Identified Stroke Biomarkers Pave Way for Blood Tests to Quickly Diagnose Brain Injuries

Each year, nearly 800,000 individuals in the U.S. experience a stroke, which occurs when blood flow to specific areas of the brain is insufficient, causing brain cells to die due to a lack of oxygen.... Read more

Immunology

view channel
Image: New insights into preterm infant immunity could inform care (Photo courtesy of 123RF)

New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood

Preterm infants are particularly vulnerable due to their organs still undergoing development, which can lead to difficulties in breathing, eating, and regulating body temperature. This is especially true... Read more

Pathology

view channel
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.